ArticleBMC health services research2026
Cost-utility of pneumococcal strategies for adults aged 50 and older in Colombia: a model-based economic evaluation.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumococcal disease remains a significant cause of morbidity, mortality, and healthcare costs among older adults in Colombia. High-valency conjugate vaccines, such as PCV20, may offer broader serotype coverage and greater clinical benefits than existing strategies; however, a local economic evaluation is required to determine their cost-effectiveness.
methodsA decision-tree model simulated a cohort of healthy adults aged 50 years or older receiving one of six vaccination strategies or no vaccination. Age-specific incidence, mortality, costs, and quality-adjusted life years (QALYs) were included. Two-time horizons (5 and 10 years, with 5 years for individuals aged 65 years or older) were modeled. Probabilistic and deterministic sensitivity analyses were used to assess uncertainty.
resultsPCV13, PCV15, PCV20, and PCV13 + PPSV23 were cost-effective against no intervention at a 10-year horizon (ICERs: $2.112, $7.630, $2.516, and $8.003 per QALY, respectively), with PCV20 having the highest probability of being the most cost-effective strategy (73.4% at an $8,266 willingness-to-pay threshold). Also, PCV20 prevented the most significant number of pneumococcal disease cases, deaths, and complications over the model horizon (1,427 deaths averted). PPSV23 and PCV15 + PPSV23 strategies were less effective and more costly over time.
conclusionsPCV20 offers the most favorable economic and clinical profile among pneumococcal vaccination strategies for Colombian adults aged 50 years and older. Its use would maximize health gains, reduce healthcare costs over time, and support efficient resource allocation within the Colombian health system. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.